Trilaciclib dihydrochloride dihydrate

Trilaciclib dihydrochloride dihydrate is used to reduce the risk of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer (ES-SCLC). It functions as a CDK4/6 inhibitor, temporarily arresting bone marrow cells in the G1 phase to protect them from chemotherapy damage. This helps decrease the incidence of neutropenia, anemia, and thrombocytopenia during chemotherapy treatment. It is grouped under the following drug class(es): CDK4/6 Inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include G1T28 dihydrochloride dihydrate and Cosela dihydrochloride dihydrate. Its PubChem CID is 155491232.

CAS No 2519335-12-5
Molecular Formula C24H36Cl2N8O3
Molecular Weight 555.5 g/mol
Synonyms 4-[[5-(4-methylpiperazin-1-yl)-2-pyridinyl]amino]spiro[1,3,5,11-tetrazatricyclo[7.4.0.02,7]trideca-2,4,6,8-tetraene-13,1′-cyclohexane]-10-one;dihydrate;dihydrochloride

Frequently Asked Questions